Sino Biopharmaceutical to buy 5% of Chia Tai-Tianqing for ~$72M

What's the deal? Sino BiopharmaceuticalDealroom has a profile for this one. Try Dealroom → (SEHK:1177) signed a sale and purchase agreement to acquire a 5% stake in Chia Tai-Tianqing Pharmaceutical HoldingsDealroom has a profile for this one. Try Dealroom → from Eric S Y Tse for CNY 480 million (about $72 million) in cash. The deal, announced on September 11, 2026, is expected to complete on September 16, 2026.

The terms: The full CNY 480 million cash consideration goes towards the common equity of Chia Tai-Tianqing. Somerley CapitalDealroom has a profile for this one. Try Dealroom → acted as financial adviser to Sino Biopharmaceutical.

The financials: For the period ending December 31, 2025, Chia Tai-Tianqing reported net income of CNY 5.82 billion. That scale underlines why even a small slice of the business carries a meaningful price tag.

The signal: By lifting its position in a profitable subsidiary, Sino Biopharmaceutical tightens its grip on one of its most valuable assets — a move that concentrates ownership as the acquirer consolidates control.

Image credit: Monash Public Library Service